| 1 Overall survival by platinum agent |
13 |
|
Hazard Ratio (Fixed, 95% CI) |
0.76 [0.69, 0.85] |
| 1.1 Cisplatin combination vs non‐platinum treatment |
8 |
|
Hazard Ratio (Fixed, 95% CI) |
0.91 [0.77, 1.08] |
| 1.2 Carboplatin combination vs non‐platinum treatment |
5 |
|
Hazard Ratio (Fixed, 95% CI) |
0.67 [0.59, 0.78] |
| 2 1‐Year OS rate by platinum agent |
13 |
1695 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.89 [0.82, 0.96] |
| 2.1 Cisplatin combination vs non‐platinum therapy |
8 |
829 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.95 [0.83, 1.08] |
| 2.2 Carboplatin combination vs non‐platinum therapy |
5 |
866 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.85 [0.76, 0.93] |
| 3 Progression‐free survival by platinum agent |
9 |
|
Hazard Ratio (Random, 95% CI) |
0.76 [0.61, 0.93] |
| 3.1 Cisplatin combination vs non‐platinum therapy |
7 |
|
Hazard Ratio (Random, 95% CI) |
0.83 [0.71, 0.97] |
| 3.2 Carboplatin combination vs non‐platinum therapy |
2 |
|
Hazard Ratio (Random, 95% CI) |
0.66 [0.38, 1.15] |
| 4 Objective response rate by platinum agent |
11 |
1432 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.57 [1.32, 1.85] |
| 4.1 Cisplatin combination vs non‐platinum therapy |
7 |
673 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.44 [1.15, 1.80] |
| 4.2 Carboplatin combination vs non‐platinum therapy |
4 |
759 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.73 [1.34, 2.23] |
| 5 Anemia by platinum agent |
11 |
1437 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.53 [1.70, 3.76] |
| 5.1 Cisplatin combination vs non‐platinum therapy |
8 |
803 |
Risk Ratio (M‐H, Fixed, 95% CI) |
4.09 [2.22, 7.55] |
| 5.2 Carboplatin combination vs non‐platinum therapy |
3 |
634 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.54 [0.90, 2.66] |
| 6 Neutropenia by platinum agent |
11 |
1413 |
Risk Ratio (M‐H, Random, 95% CI) |
1.46 [0.76, 2.81] |
| 6.1 Cisplatin combination vs non‐platinum therapy |
8 |
779 |
Risk Ratio (M‐H, Random, 95% CI) |
1.37 [0.50, 3.75] |
| 6.2 Carboplatin combination vs non‐platinum therapy |
3 |
634 |
Risk Ratio (M‐H, Random, 95% CI) |
1.95 [0.62, 6.12] |
| 7 Febrile neutropenia by platinum agent |
8 |
1215 |
Risk Ratio (M‐H, Random, 95% CI) |
1.58 [0.56, 4.50] |
| 7.1 Cisplatin combination vs non‐platinum therapy |
6 |
649 |
Risk Ratio (M‐H, Random, 95% CI) |
1.14 [0.17, 7.67] |
| 7.2 Carboplatin combination vs non‐platinum therapy |
2 |
566 |
Risk Ratio (M‐H, Random, 95% CI) |
2.30 [0.97, 5.46] |
| 8 Thrombocytopenia by platinum agent |
9 |
1260 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.59 [2.22, 5.82] |
| 8.1 Cisplatin combination vs non‐platinum therapy |
6 |
626 |
Risk Ratio (M‐H, Fixed, 95% CI) |
4.34 [2.12, 8.91] |
| 8.2 Carboplatin combination vs non‐platinum therapy |
3 |
634 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.02 [1.57, 5.79] |
| 9 Fatigue by platinum agent |
7 |
1150 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.56 [1.02, 2.38] |
| 9.1 Cisplatin combination vs non‐platinum therapy |
5 |
584 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.40 [0.75, 2.61] |
| 9.2 Carboplatin combination vs non‐platinum therapy |
2 |
566 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.71 [0.95, 3.05] |
| 10 Emesis by platinum agent |
8 |
1193 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.64 [1.82, 7.29] |
| 10.1 Cisplatin combination vs non‐platinum therapy |
6 |
627 |
Risk Ratio (M‐H, Fixed, 95% CI) |
4.80 [2.02, 11.42] |
| 10.2 Carboplatin combination vs non‐platinum therapy |
2 |
566 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.84 [0.54, 6.31] |
| 11 Peripheral neuropathy by platinum agent |
5 |
776 |
Risk Ratio (M‐H, Fixed, 95% CI) |
7.02 [2.42, 20.41] |
| 11.1 Cisplatin combination vs non‐platinum therapy |
3 |
210 |
Risk Ratio (M‐H, Fixed, 95% CI) |
4.40 [1.06, 18.31] |
| 11.2 Carboplatin combination vs non‐platinum therapy |
2 |
566 |
Risk Ratio (M‐H, Fixed, 95% CI) |
11.01 [2.11, 57.53] |
